Loading...
Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease
Gress, Kyle Bass, Julie A. Funk, Ryan S. Morrow, Ryan P. Hasenkamp, Rachel Shakhnovich, Valentina
Gress, Kyle
Bass, Julie A.
Funk, Ryan S.
Morrow, Ryan P.
Hasenkamp, Rachel
Shakhnovich, Valentina
Citations
Altmetric:
Abstract
The advent of biological therapies drastically altered the landscape of inflammatory bowel disease (IBD) treatment, making long-term steroid-free remission possible for thousands of patients living with this chronic inflammatory condition that compromises the integrity of the gastrointestinal mucosa. Unfortunately, up to 65% of patients with IBD develop anti-drug antibodies to biologics (1). This is especially problematic for pediatrics, where treatment options are substantially more limited than for adult patients. Currently, only two biologics have approval from the United States (U.S.) Food and Drug Administration (FDA) for pediatric indications in IBD, anti-TNF-α agents infliximab (IFX), and adalimumab (ADM). The fear of losing these two agents to immunogenicity is very real for the providers and the families of the ~70,000 children affected by IBD in the U.S. (2).
Description
Date
2020-06-09
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media
Collections
Files
Loading...
Gress_2020.pdf
Adobe PDF, 239.46 KB
Research Projects
Organizational Units
Journal Issue
Keywords
Immunogenicity, Children, Inflammatory bowel disease, TNF-α, Infliximab, Adalimumab, Biologics, Anti-drug antibodies
Citation
Gress K, Bass JA, Funk RS, Morrow RP, Hasenkamp R and Shakhnovich V (2020) Facing Real-World Challenges of Immunogenicity in Pediatric Inflammatory Bowel Disease. Front. Immunol. 11:1148. doi: 10.3389/fimmu.2020.01148